“The Evaluation of SATB2 as a Diagnostic Immunohistochemical Marker of Colorectal Adenocarcinoma in Comparison with Non-Colorectal Adenocarcinomas”, Journal of Pharmaceutical Negative Results, pp. 2280–2289, Feb. 2023, doi: 10.47750/pnr.2023.14.02.278.